Published : 10 Jul 2023

---

Aagami are glad to announce that a Japan and US based Biotech has appointed Aagami to support fundraising and partnering of their portfolio of intranasal drugs, targeting CNS conditions, such as Alzheimer’s disease, FTD, ALS, Dementia with Lewy Bodies, and Parkinson’s Disease.

 

Patent: 2 PCT applications filed and granted

 

A Double-blinded, Placebo-controlled Clinical Research data showing efficacy confirmed by CSF NfL.

 

Development stage: 1. About to enter clinic 2. Pre-clinical

Forecasted sales once in the market: US$4.8 Billion

 

Funds Raised: US$2.7M  seed + US$200,000 grant

 

We are open to discuss potential synergies and investments in the client’s Series A Investment round of US$15 Million.

 

If you would like to know more about this opportunity, please contact us.